

CANCER GENOMICS & PROTEOMICS

www.iar-anticancer.org, www.iarjournals.org

Print ISSN: 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004), VOL. 2 (2005), VOL. 3 (2006), VOL. 4 (2007),
VOL. 5 (2008), VOL. 6 (2009), VOL. 7 (2010), VOL. 8 (2011)

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research** and is available online with **Stanford University HighWire Press**: For more information please visit our websites www.iar-anticancer.org and www.iarjournals.org.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: journals@iar-anticancer.org (Editorial Office); IAR websites: www.iar-anticancer.org and www.iarjournals.org

Free specimen copies of CGP are available on request.

A Selection of Recent Papers

Meta-data Analysis as a Strategy to Evaluate Individual and Common Features of Proteome Changes in Breast Cancer. O. ZAKHARCHENKO, C. GREENWOOD, A. LEWANDOWSKA, U. HELLMAN, L. ALLDRIDGE, S. SOUCHELNITSKYI (*Stockholm; Uppsala, Sweden; Chelmsford, UK; Olsztyn, Poland; Gold Coast, QLD, Australia*)

Circadian Transcription Profile of Mouse Breast Cancer under LD and DD Conditions. E.-Y. OH, X. YANG, A. FRIEDMAN, C.M. ANSELL, J. DU-QUITON, D.F. QUITON, P.A. WOOD, W.J.M. HRUSHESKY (*Columbia, SC; St. Louis, MO, USA*)

Interleukin 6/Interleukin 6 Receptor Interaction and its Role as a Therapeutic Target for Treatment of Cachexia and Cancer. U.H. WEIDLE, S. KLOSTERMANN, D. EGGLE, A. KRÜGER (*Munich, Germany*)

A Biotin Label-based Antibody Array for High-content Profiling of Protein Expression. R. HUANG, W. JIANG, J. YANG, Y.Q. MAO, Y. ZHANG, W. YANG, D. YANG, B. BURKHOLDER, R.F. HUANG, R.-P. HUANG (*Norcross, GA, USA; Guangzhou, P.R. China*)

TGF- β 1 Interactome: Metastasis and Beyond. M. PERERA, C.S. TSANG, R.J. DISTEL, J.N. LACY, L. OHNO-MACHADO, V. RICCHIUTI, L.P. SAMARANAYAKE, G.B. SMEJKAI, M.G. SMITH, A.J. TRACHTENBERG, W.P. KUO (*Hong Kong, Hong Kong; Boston, MA; Ormond Beach, FL; La Jolla, CA, USA*)

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma. T. RIBARSKA, M. INGENWERTH, W. GOERING, R. ENGERS, W.A. SCHULZ (*Düsseldorf, Germany*)

Molecular Profiling Using Tissue Microarrays as a Tool to Identify Predictive Biomarkers in Laryngeal Cancer Treated with Radiotherapy. G. HOLLGERSSON, S. EKMAN, J. REIZENSTEIN, M. BERGQVIST, F. PONTÉN, M. UHLÉN, K. MAGNUSSON, P. JONNALAGADDA, A. ASPLUND, S. STRÖMBERG, A. LINDER, E. BLOMQUIST, M. LILJEHOLM, B. LÖDÉN, K. HELLSTRÖM, S. BERGSTRÖM (*Uppsala; Örebro; Gävle; Karlstad; Stockholm; Sweden; Mumbai, India*)

Proteomic Study of Sera from Patients with Bladder Cancer: Usefulness of S100A8 and S100A9 Proteins. S. MINAMI, Y. SATO, T. MATSUMOTO, T. KAGEYAMA, Y. KAWASHIMA, K. YOSHIO, J.-I. ISHII, K. MATSUMOTO, R. NAGASHIO, I. OKAYASU (*Kanagawa, Japan*)

Analysis of Protein Phosphorylation in Cisplatin-treated Human Cells Following Annexin V-based Separation and Multi-Antibody Screening. E. O'MEARA, S. CRUET-HENNEQUART, M.P. CARTY (*Galway, Ireland*)

Identification of Melanoma Antigens Using a Serological Proteome Approach (SERPA). A. SUZUKI, A. IIZUKA, M. KOMIYAMA, M. TAKIKAWA, A. KUME, S. TAI, C. OHSHITA, A. KURUSU, Y. NAKAMURA, A. YAMAMOTO, N. YAMAZAKI, S. YOSHIKAWA, Y. KIYOHARA, Y. AKIYAMA (*Shizuoka; Tokyo; Saitama, Japan*)

DNA-based Assay for EPHB6 Expression in Breast Carcinoma Cells as a Potential Diagnostic Test for Detecting Tumor Cells in Circulation. B.P. FOX, R.P. KANDPAL (*Pomona, CA, USA*)

Discovery of Serum Protein Biomarkers for Prostate Cancer Progression by Proteomic Analysis. J.A. ALRUWAILI, S.ET. LARKIN, B.A. ZEIDAN, M.G. TAYLOR, C.N. ADRA, C.L. AUKIM-HASTIE, P.A. TOWNSEND (*Hampshire, UK; Riyadh, Kingdom of Saudi Arabia; Boston, MA, USA*)

Effects of Artesunate on Cytokinesis and G2/M Cell Cycle Progression of Tumour Cells and Budding Yeast. L. STEINBRÜCK, G. PEREIRA, T. EFFERTH (*Heidelberg; Mainz, Germany*)

Use of NG2 (7.1) in AML as a Tumor Marker and its Association with a Poor Prognosis. K. PETROVICI, M. GRAF, K. HECHT, S. REIF, K. PFISTER, H. SCHMETZER (*Regensburg; Munich, Germany*)

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios
International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO, CANCER GENOMICS and PROTEOMICS.
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2011 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Immunohistochemical Expression and Prognostic Significance of CCND3, MCM2 and MCM7 in Hodgkin's Lymphoma. A. MARNERIDES, T.P. VASSILAKOPOULOS, E. BOLTETSOU, G. LEVIDOU, M.K. ANGELOPOULOU, I. THYMARA, M.-C. KYRTSONIS, V. PAPPIS, O. TSOPRA, P. PANAYIOTIDIS, G.A. PANGALIS, P. BERIS, E. PATSOIRIS, P. KORKOLOPOULOU (<i>Athens, Greece; Stockholm, Sweden</i>)	3585
Expression of Zinc Finger 23 Gene in Human Hepatocellular Carcinoma. Y. SHI, L. ZHENG, G. LUO, J. WEI, J. ZHANG, Y. YU, Y. FENG, M. LI, N. XU (<i>Changzhou, PR China; Lund, Sweden</i>)	3595
Interaction of <i>CCND1</i> Genotype and Smoking Habit in Taiwan Lung Cancer Patients. T.-C. HSIA, C.-J. LIU, C.-H. LIN, W.-S. CHANG, C.-C. CHU, L.-W. HANG, H.-Z. LEE, W.-C. LO, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	3601
Identification of The Distinctive Type <i>i/XhoI+</i> Strain of Epstein-Barr Virus in Gastric Carcinoma in Peru. P. ORDONEZ, C. KORIYAMA, S. DING, E. YOSHIWARA, A.H. CORVALAN, J. TAKANO, J.L. CHIRINOS, J. WATANABE, J. MIYAGUI, H. HIDALGO, P. CHACON, V. LINARES, Y. EIZURU, S. AKIBA (<i>Kagoshima, Japan; Lima; Huanuco; Chiclayo, Peru; Santiago, Chile</i>)	3607
Lower Serum Total Testosterone is Associated with Lymph Node Metastases in a Radical Prostatectomy Cohort Study. C. KRATZIK, I. WOMASTEK, C. BIEGLMAYER, G. SCHATZL, J. LACKNER, C. FREIBAUER, G. LUNGLMAYR (<i>Wien; Mistelbach, Austria</i>)	3615
Vitamin D in Colorectal, Breast, Prostate and Lung Cancer: A Pilot Study. P. PAZDIORA, S. SVOBODOVA, R. FUCHSOVA, R. KUČERA, M. PRAZAKOVA, J. VRZALOVA, A. NARSANSKA, M. STRAKOVA, I. TRESKOVA, L. PECEN, V. TRESKA, L. HOLUBEC JR., M. PESEK, J. FINEK, O. TOPOLCAN (<i>Pilsen; Prague, Czech Republic</i>)	3619
Effect of Ibandronate on Disseminated Tumor Cells in the Bone Marrow of Patients with Primary Breast Cancer: A Pilot Study. O. HOFFMANN, B. AKTAS, C. GOLDNAU, M. HEUBNER, C. OBERHOFF, R. KIMMIG, S. KASIMIR-BAUER (<i>Essen, Germany</i>)	3623
Association of Caveolin-1 Genotypes with Nasopharyngeal Carcinoma Susceptibility in Taiwan. Y.-A. TSOU, C.-W. TSAI, M.-H. TSAI, W.-S. CHANG, F.-J. LI, Y.-F. LIU, C.-F. CHIU, C.-C. LIN, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	3629
An Evaluation of Prognostic Value of Death-associated Protein Kinase 1 in Breast Cancer. S.-E. CHOU, C.-Y. HUANG, S.-M. SHEEN-CHEN, Y.-W. LIU, C.-H. TSAI, Y.-H. LIN, C.-C. HUANG, R.-P. TANG (<i>Kaohsiung; Linkou, Taiwan, ROC; Xiamen, PR China</i>)	3633
Errata	3637
Book Reviews	3639
Announcements	3643

* Reviews (pages 3489, 3503, 3543)

Oxaliplatin Scale and National Cancer Institute-Common Toxicity Criteria in the Assessment of Chemotherapy-induced Peripheral Neuropathy. A.-L. KAUTIO, M. HAANPÄÄ, H. KAUTIAINEN, A. LEMINEN, E. KALSO, T. SAARTO (<i>Helsinki; Jyväskylä; Tampere, Finland</i>)	3493
Bowel Complication during Robotic-assisted Laparoscopic Radical Prostatectomy. C.-F. HUNG, C.-K. YANG, C.-L. CHENG, Y.-C. OU (<i>Taichung, Taiwan, ROC</i>)	3497
* Review: The Prognostic Role of Lymphovascular Invasion in Urothelial-cell Carcinoma of Upper and Lower Urinary Tract. E. BRUNOCILLA, R. PERNETTI, G. MARTORANA (<i>Bologna, Italy</i>)	3503
Sunitinib Re-challenge in Metastatic Renal Cell Carcinoma Treated Sequentially with Tyrosine Kinase Inhibitors and Everolimus. B. PAULE, N. BRION (<i>Creteil; Guyancourt, France</i>)	3507
Significant Association of Caveolin-1 (<i>CAVI</i>) Genotypes with Breast Cancer in Taiwan. L.-C. LIU, C.-H. SU, H.-C. WANG, C.-W. TSAI, W.-S. CHANG, C.-Y. HO, C.-I WU, F.-J. LI, C.-H. LIN, H.-Y. LANE, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	3511
Endoscopic Appearance and Clinicopathological Character of Breast Cancer. D. YAMAMOTO, Y. TSUBOTA, H. YOSHIDA, S. KANEMATSU, N. SUEOKA, Y. UEMURA, K. TANAKA, A-H. KWON (<i>Osaka, Japan</i>)	3517
Expression of Thymidylate Synthase and Dihydropyrimidine Dehydrogenase in Primary Oral Squamous Cell Carcinoma and Corresponding Metastases in Cervical Lymph Nodes: Association with the Metastasis Suppressor CD82. G. KAWASAKI, I. YOSHITOMI, S. YANAMOTO, S.-I. YAMADA, A. MIZUNO, M. UMEDA (<i>Nagasaki, Japan</i>)	3521
Severe Late Complications in Patients with Uterine Cancer Treated with Postoperative Radiotherapy. G. KASUYA, K. OGAWA, S. IRAHA, Y. NAGAI, M. SHIRAISHI, M. HIRAKAWA, H. SAMURA, T. TOITA, Y. KAKINOHANA, W. KUDAKA, M. INAMINE, T. ARIGA, T. NISHIMAKI, Y. AOKI, S. MURAYAMA (<i>Okinawa, Japan</i>)	3527
Docetaxel plus 5-Fluorouracil and Cisplatin (DCF) Induction Chemotherapy for Locally Advanced Borderline-resectable T4 Esophageal Cancer. T. YOKOTA, S. HATOOKA, T. URA, T. ABE, D. TAKAHARI, K. SHITARA, M. NOMURA, C. KONDO, A. MIZOTA, Y. YATABE, M. SHINODA, K. MURO (<i>Nagoya, Japan</i>)	3535
* Review: The Role of Chemotherapy in Metastatic Gastric Cancer. F. PASINI, A.P. FRACCON, G. DE MANZONI (<i>Rovigo; Verona, Italy</i>)	3543
Hypofractionated Radiotherapy with or without IGRT in Prostate Cancer: Preliminary Report of Acute Toxicity. M. VALERIANI, F. MONACO, M.F. OSTI, V. DE SANCTIS, G. MINNITI, R.M. ENRICI (<i>Rome, Italy</i>)	3555
Changes in Serial Magnetic Resonance Spectroscopy Predict Outcome in High-grade Glioma During and After Postoperative Radiotherapy. H. QUON, B. BRUNET, A. ALEXANDER, A. MURTHA, B. ABDULKARIM, D. FULTON, M. SMERDELY, M. JOHNSON, R. URTASUN, S. PATEL, S. GHOSH, W. ROA (<i>Edmonton, AB, Canada</i>)	3559
Efficacy of Meloxicam in Combination with Preoperative Chemotherapy for Breast Cancer - Japan Breast Cancer Research Network (JBCRN) 02-1 Trial. D. YAMAMOTO, S. IWASE, H. YOSHIDA, Y. KURODA, C. YAMAMOTO, K. KITAMURA, H. ODAGIRI, Y. NAGUMO (<i>Osaka; Tokyo; Fukuoka; Hirosaki, Japan</i>)	3567
Metabolic Activation of Irinotecan during Intra-arterial Chemotherapy of Metastatic Colorectal Cancer. M. CZEJKA, A. KISS, C. KOESSNER, R. TERKOLA, D. ETTLINGER, J. SCHUELLER (<i>Vienna, Austria</i>)	3573
Long-term Disease-free Survival Following Dendritic Cell Therapy and Resection of Small Bowel Melanoma Metastases – A Case Report. K. VANDERLINDEN, S. WILGENHOF, N. VAN DE WINKEL, C. GEERS, K. THIELEMANS, B. NEYNS, K. DE VOGELAERE, G. DELVAUX (<i>Brussels, Belgium</i>)	3579

Antiproliferative Effects of N-Heterocyclic Indolyl Glyoxylamide Derivatives on Human Lung Cancer Cells. T.-H. HUANG, S.-J. CHIU, P.-H. CHIANG, S.-H. CHIOU, W.-T. LI, C.-T. CHEN, C.A. CHANG, J.-C. CHEN, Y.-J. LEE (<i>Taipei; Hualien; Zhunan, Taiwan, ROC</i>).....	3407
Tumor Endothelial Marker 8 Expression in Triple-negative Breast Cancer. L.G. GUTWEIN, S.Z. AL-QURAN, S. FERNANDO, B.S. FLETCHER, E.M. COPELAND, S.R. GROBMYER (<i>Gainesville, FL, USA</i>).....	3417
<i>Clinical Studies</i>	
Clinical Value of Combined Detection of Serum Matrix Metalloproteinase-9, Heparanase, and Cathepsin for Determining Ovarian Cancer Invasion and Metastasis. W. ZHANG, H.-C. YANG, Q. WANG, Z.-J. YANG, H. CHEN, S.-M. WANG, Z.-M. PAN, B.-J. TANG, Q.Q. LI, L. LI (<i>Guangxi, PR China; Bethesda, MD, USA</i>) ...	3423
Case Report of Pneumatosis Intestinalis Secondary to Sunitinib Treatment for Refractory Gastrointestinal Stromal Tumor. A. JARKOWSKI III, R. HARE, V. FRANCESCUTTI, N. WILKINSON, N. KHUSHALANI (<i>Buffalo, NY, USA</i>).....	3429
Diagnostic Value of 16 Cellular Tumor Markers for Metastatic Thyroid Cancer: An Immunohistochemical Study. H. LIANG, Y. ZHONG, Z. LUO, Y. HUANG, H. LIN, S. ZHAN, K. XIE, Q.Q. LI (<i>Beihai; Nanning; Pingnal; Guangzhou, China; Bethesda, MD, USA</i>)	3433
Conventional Cytogenetics and Breakpoint Distribution by Fluorescent <i>In Situ</i> Hybridization in Patients with Malignant Hemopathies Associated with inv(3)(q21;q26) and t(3;3)(q21;q26). E. DE BRAEKELEER, N. DOUET-GUILBERT, A. BASINKO, C. BOVO, N. GUÉGANIC, M.-J. LE BRIS, F. MOREL, M. DE BRAEKELEER (<i>Brest, France</i>)	3441
Phase II Study of Topotecan with Cisplatin in Japanese Patients with Small Cell Lung Cancer. Y. HOSOMI, M. SHIBUYA, S. NIHO, Y. ICHINOSE, K. KIURA, H. SAKAI, K. TAKEDA, S. KUDO, K. EGUCHI, K. MATSUI, N. MASUDA, M. ANDO, K. WATANABE (<i>Tokyo; Chiba; Fukuoka; Okayama; Saitama; Osaka; Kanagawa; Fukushima, Japan</i>)	3449
Erlotinib in First-line Therapy for Non-small Cell Lung Cancer: A Prospective Phase II Study. D.R. CHOI, D.H. LEE, C.-M. CHOI, S.-W. KIM, C. SUH, J.-S. LEE (<i>Seoul, Republic of Korea</i>)	3457
Clinicopathological Study of Poorly Differentiated Colorectal Adenocarcinomas: Comparison between Solid-type and Non-solid-type Adenocarcinomas. K. KOMORI, Y. KANEMITSU, S. ISHIGURO, Y. SHIMIZU, T. SANO, S. ITO, T. ABE, Y. SENDA, K. MISAWA, Y. ITO, N. UEMURA, T. KATO (<i>Nagoya, Aichi, Japan</i>)	3463
Uterobrush Method in the Detection of Endometrial Pathology. C. IAVAZZO, G. VORGIAS, G. MASTORAKOS, G. STEFANATOU, A. PANOUSI, A. ALEXIADOU, S. PLYTA, C. LEKKA, N. KALINOGLU, V. DERTIMAS, T. AKRIVOS, S. FOTIOU (<i>Athens; Piraeus, Greece</i>)	3469
Expression Status of Ribonucleotide Reductase Small Subunits hRRM2/p53R2 as Prognostic Biomarkers in Stage I and II Non-small Cell Lung Cancer. N.-Y. HSU, J.-Y. WU, X. LIU, Y. YEN, C.-Y. CHEN, M.-C. CHOU, C.-H. LIN, H. LEE, Y.-W. CHENG (<i>Taichung; Hsinchu, Taiwan, ROC; Duarte, CA, USA</i>)	3475
Patterns of Failures in Endometrial Cancer: Clinicopathological Variables Predictive of the Risk of Local, Distant and Retroperitoneal Failure. A. GADDUCCI, S. COSIO, M.G. FABRINI, A. FANUCCHI, C. BARSOTTI, R. CRISTOFANI, C. GRECO, A.R. GENAZZANI (<i>Pisa, Italy</i>)	3483
* Review: No Detection of BK Virus, JC Virus, KI, WU and Merkel Cell Polyomaviruses in Cerebrospinal Fluid of Patients with Neurological Complications after Hematopoietic Stem Cell Transplantation. J. RUBIN, G. GIRAUD, P. PRIFTAKIS, K. WIDE, B. GUSTAFSSON, T. RAMQVIST, T. DALIANIS (<i>Stockholm; Eskilstuna, Sweden</i>)	3489

Polo-like Kinase 1 Inhibition as a New Therapeutic Modality in Therapy of Cholangiocarcinoma. S. THRUM, J. LORENZ, J. MÖSSNER, M. WIEDMANN (<i>Leipzig; Berlin, Germany</i>)	3289
Phytoestrogens Induce Apoptosis <i>via</i> Extrinsic Pathway, Inhibiting Nuclear Factor- κ B Signaling in HER2-overexpressing Breast Cancer Cells. H.S. SEO, HAN SEOK CHOI, HYEONG SIM CHOI, Y.K. CHOI, J.-Y. UM, I. CHOI, Y.C. SHIN, S.-G. KO (<i>Seoul, Republic of Korea</i>)	3301
Biodistribution of ^{131}I -labeled Anti-CK8 Monoclonal Antibody in HNSCC in Xenotransplanted SCID Mice. M. ANDRATSCHKE, C.W. LUEBBERS, V. JOHANNSON, B. SCHMITT, B. MACK, R. ZEIDLER, S. LANG, B. WOLLENBERG, F.J. GILDEHAUS (<i>Munich; Luebeck; Essen, Germany</i>)	3315
Combination of Resveratrol and Antiandrogen Flutamide Has Synergistic Effect on Androgen Receptor Inhibition in Prostate Cancer Cells. L. KAI, A.S. LEVENSON (<i>Jackson, MS, USA</i>).....	3323
Up-regulation of 42 kDa Tubulin Alpha-6 Chain Fragment in Well-differentiated Hepatocellular Carcinoma Tissues from Patients Infected with Hepatitis C Virus. Y. KURAMITSU, M. TAKASHIMA, Y. YOKOYAMA, N. IIZUKA, T. TAMESA, J.K. AKADA, Y. WANG, T. TODA, I. SAKAIDA, K. OKITA, M. OKA, K. NAKAMURA (<i>Ube; Tokyo, Japan</i>)	3331
Effects of Non-motorized Voluntary Running on Experimental and Spontaneous Metastasis in Mice. L. YAN, L.C. DEMARS (<i>Grand Forks, ND, USA</i>)	3337
Differential Expression of Apoptosis, Cell Cycle Regulation and Intermediate Filament Genes in Oral Squamous Cell Carcinomas Associated with <i>Toombak</i> Use in Sudan. M.M. JALOULI, J. JALOULI, D. SAPKOTA, S.O. IBRAHIM, L. SAND, J.-M. HIRSCH (<i>Uppsala, Sweden; Bergen, Norway</i>)	3345
ERas Enhances Resistance to CPT-11 in Gastric Cancer. E. KUBOTA, H. KATAOKA, M. TANAKA, Y. OKAMOTO, M. EBI, Y. HIRATA, K. MURAKAMI, T. MIZOSHITA, T. SHIMURA, Y. MORI, S. TANIDA, T. KAMIYA, M. AOYAMA, K. ASAI, T. JOH (<i>Nagoya, Japan</i>)	3353
Antitumor Effect of New HER2 Peptide Vaccination Based on B Cell Epitope. H. MIYAKO, Y. KAMETANI, I. KATANO, R. ITO, B. TSUDA, A. FURUKAWA, Y. SAITO, D. ISHIKAWA, K. OGINO, S. SASAKI, K. IMAI, S. HABU, H. MAKUUCHI, Y. TOKUDA (<i>Kanagawa; Saitama; Tokushima; Hokkaido; Tokyo, Japan</i>).....	3361
Effects of Acute and Chronic Hypoxia on the Radiosensitivity of Gastric and Esophageal Cancer Cells. Y. KATO, M. YASHIRO, Y. FUYUHIRO, S. KASHIWAGI, J. MATSUOKA, T. HIRAKAWA, S. NODA, N. AOMATSU, T. HASEGAWA, T. MATSUZAKI, T. SAWADA, M. OHIRA, K. HIRAKAWA (<i>Osaka, Japan</i>)	3369
Down-regulation of EGFL8: A Novel Biomarker for Advanced Gastric Cancer. F. WU, A. SHIRAHATA, K. SAKURABA, Y. KITAMURA, T. GOTO, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI (<i>Guangzhou, China; Yokohama, Japan</i>)	3377
Increased Soluble Leptin Receptor Levels Are Associated with Advanced Tumor Stage in Colorectal Cancer Patients. V. TUTINO, M. NOTARNICOLA, V. GUERRA, D. LORUSSO, M.G. CARUSO (<i>Castellana Grotte, Bari, Italy</i>)	3381
Low-Dose Combinations of LBH589 and TRAIL Can Overcome TRAIL-resistance in Colon Cancer Cell Lines. S.-C. LEE, H.-J. CHEONG, S.-J. KIM, J. YOON, HAN JO KIM, K.H. KIM, S.H. KIM, HYUN JUNG KIM, S.B. BAE, C.-K. KIM, N. LEE, K.T. LEE, S.K. PARK, D.S. HONG, H.S. PARK, J.-H. WON (<i>Seoul; Gyeonggi-Do; Chungchungnam-Do, Republic of Korea</i>)	3385
Thiamine Supplementation Attenuated Hepatocellular Carcinoma in the Atp7b Mouse Model of Wilson's Disease. C.T. SHELINE (<i>New Orleans, LA, USA</i>).....	3395
Effects of Cytokinins, Cytokinin Ribosides and their Analogs on the Viability of Normal and Neoplastic Human Cells. S. CASATI, R. OTTRIA, E. BALDOLI, E. LOPEZ, J.A.M. MAIER, P. CIUFFREDA (<i>Milan, Italy</i>)	3401

TGF- β Regulation of Focal Adhesion Proteins and Motility of Premalignant Oral Lesions <i>via</i> Protein Phosphatase 1. J.E. WALSH, M.R. YOUNG (<i>Charleston, SC, USA</i>)	3159
Anticancer Activity of Branched-chain Derivatives of Oleic Acid. O.D. DAILEY JR., X. WANG, F. CHEN, G. HUANG (<i>New Orleans, LA; Clemson, SC, USA</i>)	3165
Enhanced Efficacy of Gemcitabine by Indole-3-carbinol in Pancreatic Cell Lines: The Role of Human Equilibrative Nucleoside Transporter 1. H. WANG, B.R. WORD, B.D. LYN-COOK (<i>Jefferson, AR, USA</i>)	3171
Silencing of Selected Glutamate Receptor Subunits Modulates Cancer Growth. H. LUKSCH, O. UCKERMANN, A. STEPULAK, S. HENDRUSCHK, J. MARZAHN, S. BASTIAN, C. STAUFNER, A. TEMME, C. IKONOMIDOU (<i>Dresden; Heidelberg, Germany; Lublin, Poland; Madison, WI, USA</i>)	3181
Paclitaxel and TRAIL Synergize to Kill Paclitaxel-resistant Small Cell Lung Cancer Cells through a Caspase-independent Mechanism Mediated through AIF. T.B. HUNTER, N.J. MANIMALA, K.A. LUDDY, T. CATLIN, S.J. ANTONIA (<i>Tampa, FL, USA</i>)	3193
Metastasis Suppressor-1, MTSS1, Acts as a Putative Tumour Suppressor in Human Bladder Cancer. P. DU, L. YE, F. RUGE, Y. YANG, W.G. JIANG (<i>Cardiff, UK; Beijing, PR China</i>)	3205
Cytotoxicity of Chalcone Derivatives towards Glioblastoma. P. CHAMPELOVIER, M. MININNO, E. DUCHAMP, E. NICOLLE, V. CURRI, A. BOUMENDJEL, J. BOUTONNAT (<i>Grenoble, France</i>)	3213
Breast Cancer Cell-derived Cytokines, Macrophages and Cell Adhesion: Implications for Metastasis. C. EICHBAUM, A.-S. MEYER, N. WANG, E. BISCHOF, A. STEINBORN, T. BRUCKNER, P. BRODT, C. SOHN, M.H.R. EICHBAUM (<i>Heidelberg, Germany; Montreal, QC, Canada</i>)	3219
Intracellular Metabolism, Subcellular Localization and Phototoxicity of HMME/HB in Ovarian Cancer Cells. K. SONG, J. LI, L. LI, P. ZHANG, F. GENG, R. DONG, Q. YANG, X. QU, B. KONG (<i>Ji'nan, Shandong, PR China</i>)	3229
The Role of the 3D Environment in Hypoxia-induced Drug and Apoptosis Resistance. J.W. KIM, W.J. HO, B.M. WU (<i>Los Angeles, CA, USA</i>)	3237
Anticancer SAR Models for MCF-7 and MDA-MB-231 Breast Cell Lines. S. QAMAR, C.A. CARRASQUER, S.L. CUNNINGHAM, A.R. CUNNINGHAM (<i>Louisville, KY, USA</i>)	3247
Down-regulation of EGFR Prolonged Cell Growth of Glioma but Did Not Increase the Sensitivity to Temozolomide. N. INABA, K. FUJIOKA, H. SAITO, M. KIMURA, K. IKEDA, Y. INOUE, S. ISHIZAWA, Y. MANOME (<i>Tokyo, Japan</i>)	3253
Fluvastatin Enhances Sorafenib Cytotoxicity in Melanoma Cells <i>via</i> Modulation of AKT and JNK Signaling Pathways. S. ZHANG, N.A. DOUDICAN, E. QUAY, S.J. ORLOW (<i>New York, NY, USA</i>)	3259
Epigenetic Modifiers Exert Renal Toxicity through Induction of p66shc. I. ARANY, J.S. CLARK, I. EMBER, L.A. JUNCOS (<i>Jackson, MS, USA; Pécs, Hungary</i>)	3267
Oncostatin M and IL-6 Induce u-PA and VEGF in Prostate Cancer Cells and Correlate <i>In Vivo</i> . T. W. WEISS, R. SIMAK, C. KAUN, G. REGA, H. PFLÜGER, G. MAURER, K. HUBER, J. WOJTA (<i>Vienna, Austria; Ullevål, Norway</i>)	3273
Prevention of Mouse Lung Tumors by Combinations of Chemopreventive Agents Using Concurrent and Sequential Administration. B.C. CASTO, M.A. PEREIRA (<i>Columbus, OH, USA</i>)	3279
Modulation of Multidrug Efflux Pump Activity by New Hydantoin Derivatives on Colon Adenocarcinoma Cells without Inducing Apoptosis. G. SPENGLER, J. HANDZLIK, I. OCSOVSZKI, M. VIVEIROS, K. KIEĆ-KONONOWICZ, J. MOLNAR, L. AMARAL (<i>Szeged, Hungary; Lisboa, Portugal; Cracow, Poland; Brussels, Belgium</i>)	3285